Analysis of tumour susceptibility using mouse models of human cancer
R. Akhurst , A. Balmain , J. H. a Mao , M. Oft
The British journal of cancer. Supplement 1 9
2000
Interaction of the HIV-1 Rev cofactor eukaryotic initiation factor 5A with ribosomal protein L5
O. Schatz , M. Oft , C. Dascher , M. Schebesta
Proceedings of the National Academy of Sciences of the United States of America 95 ( 4) 1607 -1612
73
1998
Inhibition of HIV-1 Replication in Lymphocytes by Mutants of the Rev Cofactor eIF-5A
D. Bevec , H. Jaksche , M. Oft , T. Wohl
Science 271 ( 5257) 1858 -1860
277
1996
Responses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors
N.M. Tannir , A. Naing , K.P. Papadopoulos , D.J. Wong
Annals of Oncology 29
2018
Durability of clinical benefit in metastatic epithelial ovarian cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy
K.A. Autio , A. Naing , A. Hung , M. Oft
Annals of Oncology 29
2018
Responses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy
A. Naing , K.A. Autio , G.S. Falchook , F. Meric-Bernstam
Annals of Oncology 29
2018
Responses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors
E.B. Garon , D.J. Wong , J.G. Schneider , R. Aljumaily
Annals of Oncology 29
1
2018
Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)
J.R. Hecht , A. Naing , G.S. Falchook , M.R. Patel
Annals of Oncology 29
1
2018
Combination of pegilodecakin and docetaxel shows synergy in tumor rejection in immune resistant TNBC model
N. Ratti , N. Shifrin , S. McCauley , R. Verma
Annals of Oncology 29
1
2018
Human papillomavirus type 6 in squamous cell carcinoma of the bladder and cervix
S.P. Wilczynski , M. Oft , N. Cook , S.Y. Liao
Human Pathology 24 ( 1) 96 -102
39
1993
P0110 Safety and anti-tumour activity of pegylated recombinant human IL-10 (AM0010) in selected advanced solid tumours
A Naing , J.R. Infante , K.P. Papadopoulos , K.A. Autio
European Journal of Cancer 51
2015
Overall responses and survival in RCC on pegilodecakin with anti-PD-1
A. Naing , J.R. Infante , D.J. Wong , W.M. Korn
European Journal of Cancer 110
2019
MA04.02 Responses and Durability in NSCLC Treated With Pegilodecakin and Anti-PD-1
E. Garon , D. Wong , J. Schneider , R. Aljumaily
Journal of Thoracic Oncology 13 ( 10)
2018
Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1
A. Naing , K.P. Papadopoulos , K.A. Autio , P.A. Ott
Annals of Oncology 27
2016
IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis
M. W. L. Teng , D. M. Andrews , N. McLaughlin , B. von Scheidt
Proceedings of the National Academy of Sciences of the United States of America 107 ( 18) 8328 -8333
95
2010
Expression of RORγt Marks a Pathogenic Regulatory T Cell Subset in Human Colon Cancer
N. R. Blatner , M. F. Mulcahy , K. L. Dennis , D. Scholtens
Science Translational Medicine 4 ( 164)
131
2012
Uses of IL-23 antagonists for the manufacture of a medicament for the treatment of tumors
Mcclanahan Terrill K , Oft Martin
2008
PEGYLATED IL-10 FOR USE IN TREATING CANCER OR TUMOR IL-10
Mumm John , Sheppard Catherine , Oft Martin , Linling Wu
2015
usos de antagonistas e agonistas de il-23 e reagentes relacionados
Mcclanahan Terrill K , Oft Martin
2006
USO DE IL-10 PEGUILADA PARA TRATAR CÂNCER
Mumm John , Sheppard Catherine , Oft Martin , Wu Lingling
2013